Fusion-associated neoantigen burden and predicted immunogenicity of CDK12 biallelic loss-of-function tumors vary substantially across cancer types | Caris Life Sciences
Portal
Order
Home / Research / Publications / Fusion-associated neoantigen burden and predicted immunogenicity of CDK12 biallelic loss-of-function tumors vary substantially across cancer types

Publications

Back

Fusion-associated neoantigen burden and predicted immunogenicity of CDK12 biallelic loss-of-function tumors vary substantially across cancer types

– Caris Life Sciences

Poster
  • Fusion rates and predicted neoantigen load varied significantly between CDK12 biallelic LOF tumors across cancer types, highlighting the value of biomarkers with a quantitative, phenotypic and/or immunogenic readout.
  • Co-occurrence of dMMR/MSI-High with CDK12 biallelic LOF correlated with a lower fusion rate and recurrent CDK12 frameshift mutations at poly-nucleotide tracts, suggesting CDK12 mutations are a secondary effect in these tumors.
  • We propose that fusion rates are linked to CDK12 alterations and may serve as useful biomarker to enhance our ability to identify responders of ICI therapy.

Download Publication

Discover
More

  • Clinical implications of molecular alterations in intraductal carcinoma of the prostate

    – Caris Life Sciences

    Poster

    Conclusions This data suggests that IDC-P harbors targetable molecular alterations in DDR genes (BRCA1/2 and CDK12) with approved targeted agents (e.g. PARP inhibitors). We also… […]

  • WRN mutated Colorectal Cancer is characterized by a distinct molecular and immunological profile

    – Caris Life Sciences

    Poster

    Introduction Werner syndrome gene (WRN) encodes a DNA helicase with an exonuclease activity that contributes to DNA repair. In cancer, WRN mutations lead to genomic… […]
Learn More

Ready to Get Started on the Journey?

Name(Required)